Amarin has announced news long awaited by investors -- a partnership with a big pharma. Although the pharma itself is not a household name, Japan's Kowa Pharmaceuticals will essentially triple the sales force for Vascepa. Sales of the high-triglyceride fighter, Amarin's sole approved product, have disappointed, and they appear headed nowhere close to Wall Street's initial peak sales estimates.
On this edition of Market Checkup, The Motley Fool's health care-focused investing show, analysts David Williamson and Michael Douglass discuss the new marketing deal, the challenges the companies will face (including a generic threat and competition from AstraZeneca), and whether this move will presage a turnaround in Amarin's stock.
